More than 50 new DRGs were introduced in the Swedish system in 2019, while two have been deleted. The changes affected nursing care, psychiatry, hospital and day case services of different major disease categories.
The following DRGs were introduced in hospital settings:
- A89R/A89O Drug delivery intravascularly in diseases of the nervous system (MDC 01)
- D89R/D89O Drug delivery intravascularly in respiratory diseases (MDC 04)
- F89R/F89O Drug delivery intravascularly in digestive disorders (MDC 06)
- H89R/H89O Intravascular drug delivery in muscular, skeletal and connective tissue disorders (MDC08)
- M89R/M89O Drug delivery intravascularly in diseases of the kidney and urinary tract (MDC 11)
- N89R/N89O Drug delivery intravascularly in male genitalia diseases (MDC12)
- O89R/O89O Drug delivery intravascularly in women's genitalia diseases, primary care (MDC 13)
- R89R/R89O Intravascular drug delivery in blood disorders, primary care (MDC 16)
- R91R/R91O Drug delivery intravascularly in myeloproliferative diseases, primary care (MDC 17)
- K89R/K89O Drug delivery intravascularly in mammary gland diseases, primary care (MDC 30)
Excluded DRGs:
- DRG X72O Drug supply, other less resource-intensive
- This DRG is removed because of a small outcome in this group and a low medical description value
- DRG R01O Spleen Texture, Outpatient
- This DRG is removed as the current procedure is not performed in an outpatient care
Split DRGs:
- DRG E19O Percutaneous cardiovascular measures, outpatient care is eliminated and replaced by two new DRGs:
- E17O Percutaneous ablation for cardiac arrhythmia, outpatient care
- E22O Other percutaneous cardiovascular action, outpatient care
- DRG A20N Implantation/replacement of nerve stimulator is removed and replaced by two new DRGs:
- DRG A21N Insertion of intracranial and vagal nerve stimulation armor
- DRG A22N Implantation/replacement of other nerve stimulation equipment
- DRG O15O Operations on uterus and adnexa is removed and replaced by three new DRGs:
- O16O Major surgery on uterus and adnexa for benign disease, outpatient care
- O17O Other operations on the cervix and adnexa for benign disease, outpatient care
- O18O Measures for in vitro fertilization, outpatient care
See full details in Swedish here.
Subscribe to our newsletter delivered every second week not to miss important reimbursement information.
Tags
Sweden
DRG
Reimbursement
Cardiac ablation
Vagus nerve stimulation
The latest related news
02
Oct 2024
On September 20, 2024, the Swedish Medical Technologies Product (MTP) Council commissioned the Dental and Pharmaceutical Benefits Agency (TLV) to perform a health economic evaluation of hybrid closed-loop systems for adults with type 1 diabetes. This evaluation is a part of the Orderly introduction framework, a staged process aimed at managing the national introduction of novel technologies. Based on the TLV assessment, the MTP Council will make recommendations to regions regarding the implementation of the technology and the criteria for use.
Read more
04
Sep 2024
The French National Authority for Health (HAS) released new recommendations about add-on reimbursement of medical devices from the meetings of the National Commission for Evaluation of Medical Devices and Health Technologies (CNEDiMTS) in August 2024. Five recommendations were published concerning the registration of medical devices or modification of registration conditions/extension of indications for the medical devices in the List of Reimbursable Products and Services (LPPR). Opinions concern cardiovascular, peripheral vascular, neuromodulation, orthopedic, and spine devices.
Read more
22
Aug 2024
On August 6, 2024, the Danish Health Data Authority opened the application period for changes in the 2026 DRG logic, including the creation of new DRG codes and changes in the grouping logic for existing DRGs. The deadline for the submission of the applications is November 8, 2024.
Read more
14
Aug 2024
On August 2, 2024, the HAS published positive opinions on the inclusion of targeted high-throughput sequencing of gene panels in the medical management of lung cancer, gastrointestinal stromal tumors, and chronic lymphocytic leukemia in the NABM Nomenclature. This is a consequence of the efforts to disburden the innovation funding budget and clean the List of IVD tests outside the Nomenclature (Liste des actes hors nomenclatures, AHN, i.e., the merged 2023 RIHN List and the Supplementary List funded outside Statutory Health Insurance via the research and innovation budget).
Read more
22
Jul 2024
On July 15, 2024, the Austrian Institute for HTA (AIHTA) published three decision support documents that provide recommendations regarding the inclusion of new medical interventions in the catalog of individual medical services (MEL) for reimbursement, as well as two updates to previous decision support documents. The decisions relate to cardiovascular, peripheral vascular, interventional radiology, neuromodulation, and endocrine technology groups.
Read more
